Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Other

Scynexis, Inc.

James Francis Dropinski

Frances A Bouffard

James M Balkovec

Alan D Adams

A Brian Jones

Kun Liu

Yong Zhang

Lin Chu

Robert A Zambias

Derek J Von Langen

Guizhen Dong

Vincent Colandrea

Deyou Sha

Joel Peter Berger

Alexander J Kim

Jan S Tkacz

Guo Q Shi

Gaochao Zhou

Alexander Elbrecht

Karen Lamb MacNaul

Akinlolu A Adefarati

Guo-Qiang Shi

Tesfaye Biftu

Sheo B Singh

Mark L Greenlee

Jinlong Jiang

Zhicai Wu

Robert R Wilkening

Danqing D Feng

Iyassu Sebhat

Milana M Maletic

Peter T Meinke

Dongfang Meng

XiaoXia Qian

Bing Li

Ping Chen

Rajan Anand

John Y L Chung

Peter Emmanuel Maligres

Artis Klapars

Petr Vachal

John J Acton, Iii

Lan Wei

Jacqueline D Hicks

John Limanto

Kenneth J Leavitt

James M Apgar

Fengqi Zhang

Feng Ye

Bruno Tse

Edward C Sherer

Debra L Ondeyka

Weiming Fan

John G Ondeyka

Yi Zang

Michael Robert Peel

Jae-Hun Kim

Bryon Ladd Simmons

Aaron J Moment

Ahmed Mamai

Clare E Gutteridge

Alan Michael Hyde

Michael Shevlin

Susan L Zultanski

Timothy James Wright

Ralph Calabria

Amude Kassim

Hao Liu

Daniel A DiRocco

Mikhail Reibarkh

Rose Mathew

Tyler A Davis

Louis Charles Campeau

Yi Ning Ji Chen

Xiaoxia Qian

Ali Shiafee

Weiguo Lui

Aileen Bouffard

Keqaing Li

John J Iii Acton

Frances Aileen Bouffard

The present invention is directed to a process for making Chloro-Substituted Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).

Process for making chloro-substituted nucleoside phosphoramidate compounds

The present invention relates to bicyclic himbacine derivatives of the formula  The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. 

Cyclic amine substituted heterocyclic CETP inhibitors

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. 

Cyclic azabenzimidazole derivatives useful as anti-diabetic agents

The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (1,3)-&#x3b2;-D-glucan synthase. The present compounds and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the present compounds and pharmaceutically acceptable salts thereof, are useful for treating or preventing antifungal infections and associated diseases and conditions.

Antifungal agents

Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

Antidiabetic oxazolidinediones and thiazolidinediones

A class of compounds having Formula I and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of developing conditions and sequelae that are associated with these diseases, such as atherosclerosis. 

Compounds for the treatment of dyslipidemia and other lipid disorders

A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

Compounds of Formula Iand the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from the group consisting of:

Therapeutic compounds for treating dyslipidemic conditions

Cyclohexapeptidyl amine compounds are disclosed of the formula:

Cyclohexapeptidyl amine compounds

Certain bisamine compounds which have a cyclohexapeptidyl nucleus and which are found to have antibiotic activity with physical properties suitable for direct use in therapeutic compositions are described. A novel process for their preparation is also described.

Cyclohexapeptidyl bisamine compounds

A compound having the formula ##STR1## in which R.sub.1 is an aminoalkyl group and ##STR2## is an acyl group and salts thereof having high antibiotic activity and being substantially free of lytic activity are described.

1-�4-hydroxy-5-aminoethyloxy-N.sup.2

A compound of the formula ##STR1## is disclosed which is useful for the treatment of fungal infections and for the treatment of infections caused by Pneumocystis carinii.

Cyclohexapeptidyl bisamine compound, compositions containing said

There are disclosed compounds of the general formula ##STR1## wherein all substituents are defined herein. The compounds are useful as antibiotic and antifungal agents.

Cyclohexapeptidyl aminoalkyl ethers

Growing community of inventors

Colts Neck, NJ, United States of America

James Francis Dropinski